India to Oman Pharmaceutical Export

The India-Oman pharmaceutical trade corridor has experienced significant growth over the past decade. In 2013-14, India's pharmaceutical exports to Oman were valued at approximately $30 million. By 2024, this figure had increased to $52.44 million, reflecting a substantial rise in bilateral trade. This growth is attributed to India's competitive pricing, adherence to international quality standards, and Oman's increasing demand for affordable healthcare solutions.

A pivotal development occurred in December 2025 with the signing of the Comprehensive Economic Partnership Agreement (CEPA) between India and Oman. This agreement granted Indian pharmaceutical products duty-free access to the Omani market, including finished medicines and vaccines. Additionally, the CEPA introduced fast-track marketing authorizations for products approved by stringent regulatory authorities such as the USFDA, EMA, UK's MHRA, and Australia's TGA. These measures have streamlined the registration process, reducing approval timelines and compliance costs for Indian exporters.

India holds a dominant position in Oman's pharmaceutical imports, accounting for a significant share of the market. In 2024, India's pharmaceutical exports to Oman were valued at $52.44 million, making it one of the leading suppliers to the Omani market. This strong market presence is bolstered by India's extensive portfolio of generic medicines, competitive pricing, and compliance with international quality standards. The CEPA further enhances India's strategic importance, providing near-universal duty-free access to the Omani market and facilitating faster market entry for Indian pharmaceutical products.

Between 2024 and 2026, several key developments have influenced the India-Oman pharmaceutical trade corridor. The CEPA, signed in December 2025, has been instrumental in enhancing trade relations by providing duty-free access and expediting regulatory approvals for Indian pharmaceutical products. Additionally, in May 2022, Oman agreed to fast-track the approval process for Indian pharmaceutical products already registered by authorities in the US, UK, and EU, further facilitating market access for Indian exporters. These developments have collectively strengthened the bilateral trade relationship and opened new avenues for Indian pharmaceutical companies in the Omani market.

Indian pharmaceutical companies seeking to register products in Oman must adhere to the guidelines set by Oman's National Drug Regulatory Authority, which follows WHO-GMP standards. The registration process involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) or electronic CTD (eCTD) format, detailing the product's quality, safety, and efficacy. Oman accepts Good Manufacturing Practice (GMP) certificates and inspection outcomes from recognized stringent regulatory authorities, including the USFDA, EMA, UK's MHRA, and Australia's TGA. This mutual recognition reduces duplication and compliance costs for Indian exporters. The CEPA further facilitates the registration process by allowing products approved by these authorities to receive marketing authorization within 90 days, subject to submission of complete assessment dossiers.

Oman requires Indian manufacturing sites to comply with WHO-GMP standards. The inspection process involves evaluating the manufacturing facilities to ensure they meet these international quality standards. Oman accepts GMP certificates and inspection outcomes from recognized stringent regulatory authorities, including the USFDA, EMA, UK's MHRA, and Australia's TGA. This mutual recognition reduces duplication and compliance costs for Indian exporters. The CEPA further facilitates the registration process by allowing products approved by these authorities to receive marketing authorization within 90 days, subject to submission of complete assessment dossiers.

To import pharmaceutical products into Oman, Indian exporters must provide several key documents:

• Certificate of Pharmaceutical Product (CPP): Confirms the product's registration and compliance with GMP standards.

• Certificate of Analysis (CoA): Details the product's quality and composition.

• GMP Certificate: Verifies that the manufacturing facility adheres to WHO-GMP standards.

These documents are essential for customs clearance and regulatory approval in Oman. The CEPA has streamlined the import process by providing duty-free access and expediting regulatory approvals for Indian pharmaceutical products.

India's pharmaceutical exports to Oman are predominantly finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products align with Oman's healthcare needs, addressing prevalent conditions such as endometrial carcinoma, colon adenocarcinoma, and ovarian adenocarcinoma. The top products exported include DREZ 10% Solution, AN3 CA for endometrial carcinoma, and various gels and creams for dermatological conditions. This focus on finished formulations caters to the demand for ready-to-use medications in Oman's healthcare system.

The CEPA has opened new avenues for Indian pharmaceutical exporters to supply a broader range of products to Oman. With duty-free access and expedited regulatory approvals, Indian companies can explore opportunities in biosimilars, novel drug formulations, and other therapeutic areas that align with Oman's evolving healthcare needs. The mutual recognition of GMP standards and fast-track marketing authorizations further enhance the attractiveness of the Omani market for Indian exporters.

Oman's increasing disease burden, aging population, and rising healthcare expenditures are significant drivers of pharmaceutical import demand. The country's healthcare system relies heavily on imports to meet the needs of its population, creating a substantial market for foreign pharmaceutical products. The CEPA's provisions, including duty-free access and expedited regulatory processes, position Indian pharmaceutical companies to effectively meet this growing demand.

Under the CEPA, Indian pharmaceutical products, including finished medicines and vaccines, receive duty-free access to the Omani market. This preferential treatment eliminates tariffs that were previously up to 5%, enhancing the price competitiveness of Indian exports. The agreement also provides for fast-track marketing authorizations for products approved by stringent regulatory authorities, further facilitating market entry.

The CEPA, signed in December 2025, is a significant bilateral trade agreement between India and Oman. It grants Indian pharmaceutical products duty-free access to the Omani market and introduces fast-track marketing authorizations for products approved by recognized stringent regulatory authorities. These provisions are expected to boost India's pharmaceutical exports to Oman and strengthen bilateral trade relations.

Oman's intellectual property and patent laws are aligned with international standards, providing protection for pharmaceutical innovations. The CEPA includes provisions for the protection of intellectual property rights, ensuring that Indian pharmaceutical companies' patents and data exclusivity are recognized and enforced in Oman. This legal framework supports the entry of Indian generic drugs into the Omani market, fostering a competitive environment.

Major sea and air routes facilitate the export of pharmaceutical products from India to Oman. Sea shipments typically depart from ports such as Nhava Sheva and Chennai, while air shipments are often routed through airports like Sahar and Chennai. Transit times vary depending on the mode of transport and specific routes but are generally efficient, ensuring timely delivery of pharmaceutical products. The CEPA's provisions have further streamlined logistics by reducing customs procedures and facilitating faster clearance.

Key export ports in India include Chennai Air, Nhava Sheva Sea (INNSA1), and Sahar Air. In Oman, major import ports handling pharmaceutical shipments are Muscat, Sohar, and Salalah. These ports are equipped with facilities to handle pharmaceutical imports, ensuring compliance with international standards and efficient processing of shipments. The CEPA has enhanced port operations by simplifying customs procedures and reducing clearance times for pharmaceutical products.

Temperature-controlled logistics are essential for maintaining the efficacy of pharmaceutical products during transit. Indian exporters adhere to Good Distribution Practice (GDP) compliance and packaging standards to ensure product integrity. The CEPA's provisions have facilitated compliance by standardizing requirements and reducing bureaucratic hurdles, allowing for more efficient cold chain management.